OPHTHALMIC DRUG DELIVERY SYSTEM AND APPLICATIONS

• US 20100233241A1
• Filed: 03/12/2010
• Published: 09/16/2010
• Est. Priority Date: 03/13/2009
• Status: Abandoned Application

• Current Assignee: Vista Scientific, LLC
• Original Assignee: Vista Scientific, LLC
• Inventors: Ellis, Jeanne Y., Leahy, Charles, Ellis, Edward
• Application Number:
  US12/722,713
• Publication Number:
  US 20100233241A1
• Time in Patent Office: Days
• US Class Current: 424/428
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61L 2300/22 Lipids, fatty acids, e.g. prostaglandins, oils, fats, waxes
• CPC Class Codes: A61L 2300/45 Mixtures of two or more drugs, e.g. synergistic mixtures
• CPC Class Codes: A61L 2300/452 Lubricants
• CPC Class Codes: A61L 2300/602 Type of release, e.g. controlled, sustained, slow
• CPC Class Codes: A61L 2430/16 for reconstruction of eye parts, e.g. intraocular lens, cornea
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics

Abstract

An ocular device for insertion into an eye is provided and includes a body having an anterior surface and a posterior surface for placement on one of superior sclera and inferior sclera of the eye. The posterior surface is defined by a base curve that is substantially identical to a radius of curvature of the one of the superior sclera and inferior sclera of the eye. In one embodiment, the ocular device serves as an ocular drug delivery system and contains an active pharmaceutical agent, a lubricant, etc. In a second embodiment the ocular device can be constructed in such a manner to treat a wide variety of ocular conditions and diseases.

Claims

1. An topical ocular system for delivery of a therapeutic agent to an eye comprising:

a body having an anterior surface and a posterior surface for placement on one of a superior sclera and inferior sclera of the eye, wherein the posterior surface is defined by a base curve and edge lift radii at peripheral edges thereof that are both complementary to and adapted to fit the sclera of the eye so as to permit the device to the held on the eye by fluid attraction and be retained on the eye without aid of an eyelid, where said ocular device matrix composed of a polymeric material, or a combination of polymeric materials, said ocular device containing a therapeutic agent, or a combination of therapeutic agents, said ocular device releasing the therapeutic agent or agents in a controlled manner, the mechanism of release is either physical/physiochemical or chemical/biochemical or a combination of the above two mechanisms.

2. An ocular system of claim 1, wherein the polymeric matrix comprises a non-erodible polymer or an erodible polymer or a combination of both.

3. An ocular system of claim 1, wherein the therapeutic agent, or a combination of therapeutic agents is dissolved in the polymeric matrix.

4. An ocular system of claim 1, wherein the therapeutic agent or a combination of therapeutic agents is dispersed in the polymeric matrix.

5. An ocular system of claim 1, wherein the therapeutic agent or a combination of therapeutic agents is contained in a reservoir either totally internal to the polymer matrix or partially exposed to the ocular environment.

6. An ocular system of claim 5, wherein the therapeutic agent or a combination of therapeutic agents is contained in a reservoir either totally internal to the polymer matrix or partially exposed to the ocular environment. The therapeutic agent or a combination of therapeutic agents forming the reservoir are either neat or admixed with a polymer.

7. An ocular system of claim 1, wherein the therapeutic agent or a combination of therapeutic agents are selected from the group consisting of:

analgesics, mydriatics and mydriolytics, antiglaucoma drugs, anti-infective drugs, anti-inflammatory drugs, antiallergy drugs, antiangiogenic drugs and lubricants.

8. An ocular system of claim 1, wherein the drug containing device is placed underneath the conjunctiva or Tenon'"'"'s capsule for drug delivery to the anterior segment and/or posterior segment of the eye.

9. An ocular system of claim 8, wherein the ocular diseases to be treated include:

glaucoma, age related macular degeneration, diabetic macular edema, uveitis, and retinitis.

10. An ocular system of claim 1, wherein the therapeutic agent or a combination of therapeutic agents is a prostaglandin alone or in combination with another ocular drug.

11. An ocular system of claim 10, wherein the prostaglandin is dispersed throughout the polymeric matrix or localized in a portion of the device.

12. An ocular system of claim 11, wherein the prostaglandin is localized in a cavity that has an exposed surface on the base curve of the device.

13. An ocular system of claim 12, wherein the prostaglandin is dispersed in a polysiloxane and is localized in a cavity that has an exposed surface on the base curve of the device.

14. An ocular system in accordance with claim 6, wherein the ocular device contains both a prostaglandin in a cavity or a prostaglandin dispersed in a polysiloxane in a cavity and another anti-glaucoma agent that is dissolved or dispersed throughout the device matrix.